Table 3.
PPI Users (n=21) | PPI Non-users (n=121) | ||||
---|---|---|---|---|---|
Measure | N (%) | M (SD) | N (%) | M (SD) | |
Age | 55.7(9.1) | 55.6(7.7) | |||
Comorbidities | 0.3(0.6) | 0.2(0.5) | |||
Months since cancer tx | 53.1(19.9) | 43.0(27.7) | |||
Race (% White) | 20(95%) | 106(88%) | |||
Education | High School | 6(29%) | 16(13%) | ||
Some College | 2(10%) | 25(21%) | |||
College Grad | 6(29%) | 37(31%) | |||
Grad Training | 7(33%) | 43(34%) | |||
Chemo tx (% Yes) | 16(80%) | 88(73%) | |||
Hormone tx (% Yes) | 14(65%) | 95(79%) | |||
Radiation tx (% Yes) | 9(43%) | 68(56%) | |||
CES-D score | 9.1(8.0) | 7.1(7.3) | |||
Cancer Stage | Stage I | 6(29%) | 50(41%) | ||
Stage II | 11(52%) | 63(52%) | |||
Stage III | 1(5%) | 8(7%) |
p<0.05